ArticleBMC pediatrics2025
A Sri Lankan boy with Emery-Dreifuss muscular dystrophy 5 presenting during infancy with persistent transaminitis.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmery-Dreifuss muscular dystrophy is a rare muscular dystrophy characterised by muscle weakness, joint contractures, and cardiac involvement. Among its subtypes, Emery-Dreifuss muscular dystrophy 5 typically presents with muscle weakness and cardiomyopathy during late childhood. Here, we report a Sri Lankan boy with Emery-Dreifuss muscular dystrophy 5 presenting with an unusual manifestation of persistent transaminitis detected during infancy. CASE PRESENTATION: A 21-month-old boy is admitted for further evaluation of high transaminases detected at nine months of age. He was the first-born child of healthy, non-consanguineous parents with an uncomplicated perinatal period. At nine months, he was found to have high transaminases (aspartate transaminase- 230IU/L and alanine transaminase- 234IU/L), which had persisted. He had marginal isolated gross motor developmental delay; however, he could walk unaided at 18 months. Examination revealed pseudohypertrophy of the calf and positive Gower's sign. Lower limb tone and tendon reflexes were normal, and there were no joint contractions. He did not have dysmorphic features or peripheral stigmata of chronic liver disease. Investigations revealed persistently high aspartate and alanine transaminases and very high creatine phosphokinase of 15625 U/L. Abdominal ultrasonography and other liver function tests were normal. Based on normal liver function tests and high creatine phosphokinase, a muscular dystrophy was suspected. The electromyogram showed features of myopathy, and the muscle biopsy was compatible with congenital muscular dystrophy. The genetic analysis of the dystrophin gene by PCR-based amplification of 19 deletion-prone exons and copy number variation analysis did not reveal deletions in the dystrophin gene. The whole exome sequencing detected a missense splice region heterozygous variant of the SYNE2 gene, confirming Emery-Dreifuss muscular dystrophy 5.
conclusionsHere, we report an extremely rare presentation of Emery-Dreifuss muscular dystrophy 5 during infancy with transaminitis. This case report highlights the importance of evaluating non-hepatic causes for elevated transaminases and the usefulness of whole exome sequencing in establishing an accurate diagnosis when relatively uncommon diseases are suspected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.